On March 19, Novo Nordisk announced the investment of around 4 billion RMB with a ground-breaking ceremony to expand the existing production site in Tianjin. Leaders from Embassy of the Kingdom of Denmark to China, Tianjin municipal government and Binhai New Area were invited to attend the ceremony and witness the initiation of the expansion project.

2024 celebrates Novo Nordisk’s 30th anniversary in China. As the birthplace of Novo Nordisk in China, one of Novo Nordisk’s strategic production facilities across the world was established in Tianjin 30 years ago. Following the investment of 1.18 billion RMB in finished production and pre-filled lines at Site Tianjin in Q1 2023, this investment in aseptic production processes marks another significant milestone. This investment will further increase Novo Nordisk’s manufacturing capacity and the ability to meet patient’s future needs of innovative medicines in China. The expansion includes a modern filling facility with isolator technology and the expansion project is expected to be completed in 2027.

Ms. Christine Zhou, Senior Vice President and President of Region China of Novo Nordisk, attended the ceremony and addressed in her speech “2024 marks Novo Nordisk’s 30th anniversary of prosperous development in China and Tianjin is where Novo Nordisk first set its footprint. Over the past 30 years, we’ve stayed focused on our commitment to people living with serious chronic diseases. With the investment, we will be able to serve even more patients in China with our innovative medicines. Through accelerating innovation and deepening cooperation, Novo Nordisk will advance the process of drug localisation while helping achieve the goals of Healthy China in 2030.”

Mr. Lars Arnoldsen, Corporate Vice President of Novo Nordisk “Our gratitude is extended for the help and support from all levels of the government over the past 30 years. As one of Novo Nordisk's strategic production bases, Site Tianjin plays an important role in our global supply chain. With the expansion project, we’ll be able to further increase manufacturing capability to support the localisation of more innovative medicines, delivering highest quality to patients.”

Novo Nordisk China was established in 1994 and investments and upgrades have been on-going within the full value chain to form “Dual Centres, Triple Engines” new strategic presence in China. “Dual Centres” refers to the two legal entities located in Tianjin and Shanghai that were certified by the local municipal governments as MNC regional headquarters. “Triple Engines” refers to the engine of trade and innovation located in Shanghai, the production engine in Tianjin, and the R&D engine in Beijing. This new strategic presence will enable the company to foster a strong and orchestrated local presence and mobilise resources to fully fulfil the commitment to China.

Located in Tianjin Economic Development Area, Novo Nordisk Site Tianjin is one of Novo Nordisk’s strategic production sites that operates with a strict quality management system adhering to industry standards and regulations. Being environmentally responsible, the site is fully powered by renewable electricity for all manufacturing activities. Currently the site employs around 1,700 people, providing highest quality to patients in China.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries.